HCLTech · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Engineering & R&D services declined 3.7% QoQ due to discretionary spending cuts by two large US telecom clients and high base effects in the technology vertical. Management acknowledged this headwind will continue in subsequent quarters, with no near-term visibility of recovery.
Analysts questioned the $7M per MW implied cost (colocation economics vs. AI data center) and whether 50MW total capacity justifies the investment. Management provided limited details on ROCE targets, funding structure beyond initial ₹3,500 crore, and how demand will absorb capacity amid global hyperscaler buildouts. Market perception that compute scarcity may be ending adds risk.
Healthcare/life sciences has been declining gradually over 8-9 quarters from a ~$500M run rate due to completion of one-time medical device regulatory work and ongoing US healthcare sector stress. Management sees no near-term turnaround catalyst, making it a persistent headwind.
Both revenue (1-4%) and margin (17.5-18.5%) guidance explicitly exclude JasperSoft and potential CDG acquisition impacts. With JasperSoft contributing only ~$10-15M quarterly, upside from acquisitions is limited, constraining overall growth trajectory and maintaining pressure on organic performance.
